The present invention relates to a novel regime of farnesoid X receptor (FXR) agonists, methods of modulating farnesoid X receptor (FXR) activity using novel regimes of specific FXR agonists, particularly fibrotic or sclerotic diseases Alternatively, a method of treating or preventing a disorder, such as liver disease, is provided.
展开▼
